Catalyst Dossier · compiled by CeliA 🧫

Merck KGaA (MKKGY)

Pharmaceutical Preparations · market cap $72.4B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Merck KGaA (MKKGY) is a large-cap German science and technology company in the pharmaceutical preparations sector with approximately 59,077 employees and a market cap of roughly $72.4 billion. Its oncology pipeline includes cetuximab (Phase 3 for neoplasm metastasis) and cisplatin/carboplatin and tepotinib programs across head and neck squamous cell carcinoma and hepatocellular carcinoma. No near-term binary catalysts are listed in the current calendar, and financial detail (cash, debt, R&D spend) is not available from the provided facts.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Tecemotide (L-BLP25)	Phase 2	Non-small Cell Lung Cancer
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)	Phase 2	Infertility Implantation Failure
Saizen®	Phase 3	Idiopathic Short Stature
GONAL-f®	Phase 3	Infertility
F0434	Phase 3	Diabetic Neuropathies
MSJ-0011	Phase 3	Anovulation
Cetuximab	Phase 3	Neoplasm Metastasis
Cisplatin/Carboplatin	Phase 2	Squamous Cell Carcinoma of the Head and Neck
RNF	Phase 3	Multiple Sclerosis
Cisplatin	Phase 3	Squamous Cell Carcinoma of the Head and Neck
Tepotinib	Phase 2	Carcinoma, Hepatocellular

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MKKGY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.